Generation Bio Net Worth
Generation Bio Net Worth Breakdown | GBIO |
Generation Bio Net Worth Analysis
Generation Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Generation Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Generation Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Generation Bio's net worth analysis. One common approach is to calculate Generation Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Generation Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Generation Bio's net worth. This approach calculates the present value of Generation Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Generation Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Generation Bio's net worth. This involves comparing Generation Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Generation Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Generation Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Generation Bio's net worth research are outlined below:
| Generation Bio generated a negative expected return over the last 90 days | |
| Generation Bio has some characteristics of a very speculative penny stock | |
| Generation Bio has high historical volatility and very poor performance | |
| Generation Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (126.61 M) with loss before overhead, payroll, taxes, and interest of (41.44 M). | |
| Generation Bio Co currently holds about 301.17 M in cash with (52.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc. |
Generation Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Generation Bio Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Generation Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Generation Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Generation Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Generation Bio Co backward and forwards among themselves. Generation Bio's institutional investor refers to the entity that pools money to purchase Generation Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prudential Financial Inc | 2024-09-30 | 51 K |
Follow Generation Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.81 M.Market Cap |
|
Project Generation Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.72) | (0.68) |
When accessing Generation Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Generation Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Generation Bio's profitability and make more informed investment decisions.
Evaluate Generation Bio's management efficiency
Generation Bio has return on total asset (ROA) of (0.1929) % which means that it has lost $0.1929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.865) %, meaning that it created substantial loss on money invested by shareholders. Generation Bio's management efficiency ratios could be used to measure how well Generation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of February 2025, Return On Tangible Assets is likely to drop to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.39. At this time, Generation Bio's Non Currrent Assets Other are very stable compared to the past year. As of the 7th of February 2025, Asset Turnover is likely to grow to 0.01, while Total Assets are likely to drop about 302.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.84 | 2.72 | |
| Tangible Book Value Per Share | 2.84 | 2.72 | |
| Enterprise Value Over EBITDA | (0.93) | (0.98) | |
| Price Book Value Ratio | 0.47 | 0.49 | |
| Enterprise Value Multiple | (0.93) | (0.98) | |
| Price Fair Value | 0.47 | 0.49 | |
| Enterprise Value | 249.5 M | 237 M |
The operational strategies employed by Generation Bio management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 5.103 | Revenue | Quarterly Revenue Growth 2.52 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Generation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Generation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Generation Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Generation Bio time-series forecasting models is one of many Generation Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Generation Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Generation Bio Earnings per Share Projection vs Actual
Generation Bio Corporate Management
| Caitlin MBA | Senior Development | Profile | |
| Robert Kotin | CoFounder Advisor | Profile | |
| Sara Besten | Chief Officer | Profile | |
| Tracy Zimmermann | Chief Officer | Profile | |
| Phillip Samayoa | Chief Officer | Profile | |
| Jasmin Tower | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Generation Bio Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share | Quarterly Revenue Growth 2.52 | Return On Assets | Return On Equity |
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.